论文部分内容阅读
目的:探讨瑞舒伐他汀钙对高血压合并高脂血症患者血压、血脂与血管活性物质的疗效。方法:选择我院于2014年9月~2015年6月收治的100例高血压合并高脂血症患者为研究对象,患者被随机均分为常规治疗组和瑞舒伐他汀组(在常规治疗组基础上加用瑞舒伐他汀钙片)。比较两组患者治疗前后血压、血脂及血清生化指标的变化情况。结果:与常规治疗组比较,瑞舒伐他汀组总有效率(82.0%比96.0%)显著升高,P=0.039。与治疗前比较,两组治疗后DBP、SBP、TC、TG、LDL-C和血清hsCRP水平显著降低(常规治疗组的TC除外),HDLC、血清NO和血浆SOD水平显著升高,P<0.05或<0.01;与常规治疗组比较,瑞舒伐他汀组治疗后DBP[(91.65±7.26)mmHg比(72.21±4.56)mmHg]、SBP[(146.24±9.87)mmHg比(125.53±10.07)mmHg]、TC[(6.07±0.48)mmol/L比(3.73±0.45)mmol/L]、TG[(2.18±0.20)mmol/L比(1.81±0.18)mmol/L]、LDL-C[(2.97±0.22)mmol/L比(1.62±0.12)mmol/L]和血清hsCRP水平[(3.21±0.45)mmol/L比(1.83±0.34)mmol/L]降低更显著,HDL-C[(0.89±0.15)mmol/L比(1.15±0.23)mmol/L]、血清NO[(33.26±4.23)mmol/L比(43.86±5.04)mmol/L]和血浆SOD水平[(23.54±3.62)mmol/L比(32.75±4.65)mmol/L]升高更显著,P均<0.01。与常规治疗组比较,瑞舒伐他汀组腹胀(8.0%比2.0%)、便秘(6.0%比4.0%)、恶心(6.0%比4.0%)和心律失常(4.0%比0)发生率显著降低,P<0.05或<0.01。结论:瑞舒伐他汀钙对高血压合并高脂血症患者疗效显著,可显著改善血脂、血压和血管内皮功能,且不良反应发生率低,值得临床推广。
Objective: To investigate the effect of rosuvastatin calcium on blood pressure, blood lipids and vasoactive substances in patients with hypertension and hyperlipidemia. Methods: A total of 100 hypertensive patients with hyperlipidemia admitted to our hospital from September 2014 to June 2015 were selected and randomly divided into routine therapy and rosuvastatin (conventional therapy Group based on the use of rosuvastatin calcium tablets). The changes of blood pressure, blood lipid and serum biochemical indexes in two groups before and after treatment were compared. Results: Compared with the conventional treatment group, the total effective rate of rosuvastatin group (82.0% vs 96.0%) was significantly higher (P = 0.039). Compared with those before treatment, the levels of DBP, SBP, TC, TG, LDL-C and serum hsCRP were significantly decreased (except TC in the conventional treatment group), HDLC, serum NO and plasma SOD levels were significantly increased Or (P <0.01). Compared with the conventional treatment group, DBP [(91.65 ± 7.26) mmHg ratio (72.21 ± 4.56) mmHg] and SBP [(146.24 ± 9.87) mmHg ratio (125.53 ± 10.07) mmHg] , And TC [(6.07 ± 0.48) mmol / L vs (3.73 ± 0.45) mmol / L], TG [2.18 ± 0.20 mmol / L vs 1.81 ± 0.18 mmol / L] 0.22 ± 0.12 mmol / L] and serum hsCRP level [(3.21 ± 0.45) mmol / L vs (1.83 ± 0.34) mmol / L] (1.15 ± 0.23) mmol / L], serum NO [(33.26 ± 4.23) mmol / L vs (43.86 ± 5.04) mmol / L] and plasma SOD [(23.54 ± 3.62) mmol / L (32.75 ± 4.65) mmol / L] increased significantly, all P <0.01. Compared with the conventional treatment group, the incidence of abdominal distension (8.0% vs. 2.0%), constipation (6.0% vs 4.0%), nausea (6.0% vs 4.0%) and arrhythmia (4.0% vs 0) were significantly lower in rosuvastatin group , P <0.05 or <0.01. Conclusion: Rosuvastatin calcium is effective in patients with hypertension and hyperlipidemia, and can significantly improve blood lipid, blood pressure and vascular endothelial function, and the incidence of adverse reactions is low, worthy of clinical promotion.